Literature DB >> 26715870

Pilot of three objective markers of physical health and chemotherapy toxicity in older adults.

T Hsu1, R Chen1, S C X Lin2, S Djalalov2, A Horgan2, L W Le3, N Leighl2.   

Abstract

BACKGROUND: Patient function is a key part of the clinical decision to offer chemotherapy and has, in earlier studies, been associated with chemotherapy toxicity. Objective testing might be more accurate than patient-reported or physician-assessed physical function, and thus might be a stronger predictor of chemotherapy toxicity in older adults.
METHODS: Patients, 70 years of age and older, with thoracic or colorectal cancer were recruited. Three physical tests were performed before commencement of a new line of chemotherapy: grip strength, 4-m walk test, and the Timed Up and Go (tug). Our pilot study explored the association between those tests and chemotherapy toxicity.
RESULTS: The 24 patients recruited had a median age of 74.5 years (range: 70-84 years), and 54.2% had an Eastern Cooperative Oncology Group performance status of 0 or 1. Median score on the Charlson comorbidity index was 1 (range: 0-4). Almost two thirds had metastatic disease, 70% were chemonaïve, and 83.3% were about to receive polychemotherapy. Patients had a mean tug of 13.2 ± 5.7 s and a mean gait speed of 0.74 ± 0.24 m/s; 50% had a grip strength test in the lowest 20th percentile. Grades 3-5 chemotherapy toxicities occurred in 34.7% of the patients; two thirds required a dose reduction or delay; and one third discontinued chemotherapy because of toxicity. Hospitalization attributable to chemotherapy was uncommon (12.5%). A trend toward increased severe chemotherapy toxicity with slower gait speed was observed (p = 0.049).
CONCLUSIONS: Abnormalities in objective markers of physical function are common in older adults with cancer, even in those deemed fit for chemotherapy. However, those abnormalities were not associated with an increased likelihood of chemotherapy toxicity in the population included in this small pilot study.

Entities:  

Keywords:  Aging; chemotherapy toxicity; elderly people; neoplasms; objective markers; older adults; physical health

Year:  2015        PMID: 26715870      PMCID: PMC4687658          DOI: 10.3747/co.22.2623

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  42 in total

1.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

Authors:  Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

2.  Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Carmela Pepe; Michele Monette; Sarit Assouline; Lawrence Panasci; Mark Basik; Wilson H Miller; Gerald Batist; Christina Wolfson; Howard Bergman
Journal:  Crit Rev Oncol Hematol       Date:  2010-05-04       Impact factor: 6.312

3.  Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.

Authors:  G Freyer; J-F Geay; S Touzet; J Provencal; B Weber; J-P Jacquin; G Ganem; N Tubiana-Mathieu; O Gisserot; E Pujade-Lauraine
Journal:  Ann Oncol       Date:  2005-08-10       Impact factor: 32.976

4.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

5.  Predictors of early death risk in older patients treated with first-line chemotherapy for cancer.

Authors:  Pierre Soubeyran; Marianne Fonck; Christèle Blanc-Bisson; Jean-Frédéric Blanc; Joël Ceccaldi; Cécile Mertens; Yves Imbert; Laurent Cany; Luc Vogt; Jerôme Dauba; Francis Andriamampionona; Nadine Houédé; Anne Floquet; Francois Chomy; Véronique Brouste; Alain Ravaud; Carine Bellera; Muriel Rainfray
Journal:  J Clin Oncol       Date:  2012-04-16       Impact factor: 44.544

6.  Midlife hand grip strength as a predictor of old age disability.

Authors:  T Rantanen; J M Guralnik; D Foley; K Masaki; S Leveille; J D Curb; L White
Journal:  JAMA       Date:  1999-02-10       Impact factor: 56.272

7.  The early discontinuation of palliative chemotherapy in older patients with cancer.

Authors:  Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Hyun Chang; Jeong-Ok Lee; Kwang-Il Kim; Soo-Mee Bang; Jong Seok Lee; Cheol-Ho Kim; Jee Hyun Kim
Journal:  Support Care Cancer       Date:  2013-11-28       Impact factor: 3.603

8.  Does frailty predict hospitalization, emergency department visits, and visits to the general practitioner in older newly-diagnosed cancer patients? Results of a prospective pilot study.

Authors:  M T E Puts; J Monette; V Girre; C Wolfson; M Monette; G Batist; H Bergman
Journal:  Crit Rev Oncol Hematol       Date:  2009-11-24       Impact factor: 6.312

9.  Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer.

Authors:  Sami Antoun; Isabelle Borget; Emilie Lanoy
Journal:  Curr Opin Support Palliat Care       Date:  2013-12       Impact factor: 2.302

10.  Physical function and self-rated health status as predictors of mortality: results from longitudinal analysis in the ilSIRENTE study.

Authors:  Matteo Cesari; Graziano Onder; Valentina Zamboni; Todd Manini; Ronald I Shorr; Andrea Russo; Roberto Bernabei; Marco Pahor; Francesco Landi
Journal:  BMC Geriatr       Date:  2008-12-22       Impact factor: 3.921

View more
  1 in total

1.  Self-reported major mobility disability and mortality among cancer survivors.

Authors:  Justin C Brown; Michael O Harhay; Meera N Harhay
Journal:  J Geriatr Oncol       Date:  2018-03-14       Impact factor: 3.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.